Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Jilin Province Huinan Changlong Bio-pharmacy Co's Enterprise Value for the quarter that ended in Dec. 2025 was €46.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jilin Province Huinan Changlong Bio-pharmacy Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €32.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co EV-to-EBIT Related Terms
Jilin Province Huinan Changlong Bio-pharmacy Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co EV-to-EBIT Chart
Jilin Province Huinan Changlong Bio-pharmacy Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Jilin Province Huinan Changlong Bio-pharmacy Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jilin Province Huinan Changlong Bio-pharmacy Co EV-to-EBIT vs Drug Manufacturers Industry
Jilin Province Huinan Changlong Bio-pharmacy Co's current Enterprise Value is €53.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jilin Province Huinan Changlong Bio-pharmacy Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €32.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) has a EV-to-EBIT of 1.68 as of Aug. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co and its competitors. This is 46% above median its historical median of 1.15. According to the industry distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #33 out of 690 companies in the Drug Manufacturers industry, placing it in the top 4.8%.
Is Jilin Province Huinan Changlong Bio-pharmacy Co's EV-to-EBIT too high?
Jilin Province Huinan Changlong Bio-pharmacy Co's current EV-to-EBIT of 1.68 is 46% above median its 10-year median of 1.15. The Drug Manufacturers industry median EV-to-EBIT is 15.57. Jilin Province Huinan Changlong Bio-pharmacy Co's value of 1.68 is 89.2% below this industry median. Based on the distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #33 out of 690 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jilin Province Huinan Changlong Bio-pharmacy Co has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jilin Province Huinan Changlong Bio-pharmacy Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #33 out of 690 companies for EV-to-EBIT. This places Jilin Province Huinan Changlong Bio-pharmacy Co in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.57. Jilin Province Huinan Changlong Bio-pharmacy Co's value of 1.68 is 89.2% below this benchmark. While the company's 10-year median is 1.15 vs. the industry median of 15.57, Jilin Province Huinan Changlong Bio-pharmacy Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.57, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jilin Province Huinan Changlong Bio-pharmacy Co's current EV-to-EBIT of 1.68 is 89.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jilin Province Huinan Changlong Bio-pharmacy Co's current EV-to-EBIT is 1.68, which is 46% above median its own 10-year median of 1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jilin Province Huinan Changlong Bio-pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.18, compared to a current price of €0.24 — trading 33.3% above its estimated fair value. The current EV-to-EBIT is 1.68, which is 46% above median its 10-year median of 1.15 and 89.2% below the Drug Manufacturers industry median of 15.57. Jilin Province Huinan Changlong Bio-pharmacy Co's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL), the current EV-to-EBIT is 1.68 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) Overvalued in 2026?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co stock appears to be overvalued.
The current stock price of €0.24 is trading 33.3% above its estimated GF Value™ of €0.18.
GuruFocus considers Jilin Province Huinan Changlong Bio-pharmacy Co to be Significantly Overvalued.
Key valuation signals for FRA:JIL:
EV-to-EBIT: 1.68 (46% above median its 10-year median of 1.15)
GF Value™: €0.18 vs. price of €0.24 (33.3% above fair value)
Industry Position: 89.2% below the Drug Manufacturers median (#33 of 690)
No single metric tells the full story. See the FRA:JIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong and Qing Tong. The company has only one business segment. It generates revenue from the Sales of Chinese medicines and pharmaceutical products. Geographically, it derives its entire revenue from the PRC.
43GF Score
Get the complete analysis for FRA:JIL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JIL has been successfully added to your 
